Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Xylazine HCl (Anased; BAY 1470; BAY-1470;Primazine; Rometar; Sedomin; WH-7286; Xilazina), the hydrochloride salt of xylazine and an analogue of clonidine, is an α2-Adrenergic receptor agonist that has been approved as a Veterinarian drug and used for sedation, muscle relaxation, anesthesia, and analgesia in big animals such as horses, cattles and other non-human mammals. Veterinarians additionally use xylazine as an emetic, particularly for cats. When naloxine is present, Xylazine significantly prolongs the analgesic effects in 40 and 50 minutes, according to analgesic testing.
Targets |
α2-adrenergic
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C12H17CLN2S
|
|
---|---|---|
Molecular Weight |
256.79
|
|
Exact Mass |
256.08
|
|
Elemental Analysis |
C, 56.13; H, 6.67; Cl, 13.80; N, 10.91; S, 12.48
|
|
CAS # |
23076-35-9
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=C(C(=CC=C1)C)NC2=NCCCS2.Cl
|
|
InChi Key |
QYEFBJRXKKSABU-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C12H16N2S.ClH/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12;/h3,5-6H,4,7-8H2,1-2H3,(H,13,14);1H
|
|
Chemical Name |
N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.8942 mL | 19.4712 mL | 38.9423 mL | |
5 mM | 0.7788 mL | 3.8942 mL | 7.7885 mL | |
10 mM | 0.3894 mL | 1.9471 mL | 3.8942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effects on the N3 field of ketamine, xylazine, and ketamine + xylazine. J Neurophysiol . 2007 Sep;98(3):1697-705. td> |
Repeated injections of ketamine and xylazine. J Neurophysiol . 2007 Sep;98(3):1697-705. td> |
Plasma glucose levels following the administration of medetomidine (MED μg/kg, A) and xylazine (XYL mg/kg, B) in dogs. Can J Vet Res . 2002 Jan;66(1):42-9. td> |
The normalised AUC (0–8 h) data of the plasma glucose graphs are plotted versus the dose of medetomidine (A) and xylazine (B). Can J Vet Res . 2002 Jan;66(1):42-9. td> |